Laurus Labs FY26 Revenue Up 23% to ₹6,813 Cr; Profit Surges 148%
Laurus Labs reported FY26 revenue of ₹6,813 Cr, up 23% YoY, driven by CDMO and Affordable Medicines. Net profit surged 148% to ₹889 Cr. Q4 FY26 revenue was ₹1,812 Cr, up 5% YoY. The company announced significant capex for growth projects and an interim dividend of ₹1.20 per share.
The substantial increase in revenue, profit, and key financial ratios, along with strategic investments and dividend payout, has a significant positive impact on the company's financial standing and investor confidence.
The company reported strong year-on-year growth in revenue and profit, along with improved margins and a reduced debt-to-EBITDA ratio. This indicates a positive financial performance and outlook.
Laurus Labs Limited announced its financial results for the quarter and year ended March 31, 2026. The company reported a significant year-on-year revenue growth of 23%, reaching ₹6,813 crore. This growth was driven by strong performance in both the CDMO and Affordable Medicines divisions. The CDMO segment saw a 36% increase in revenue to ₹2,080 crore, while the Affordable Medicines division grew by 18% to ₹4,733 crore.
Full-year EBITDA increased by 64% to ₹1,826 crore, with EBITDA margins expanding by 670 basis points to 26.8%. Net profits surged by 148% to ₹889 crore, and Earnings Per Share (EPS) grew to ₹16.4 from ₹6.6 in the previous year. Operating cash flow also saw a substantial increase of 170% to ₹1,624 crore. The company reduced its Net Debt to EBITDA ratio to 1.3x from 2.3x and improved its Return on Capital Employed (ROCE) to 17.7%.
For the fourth quarter of FY26, revenues were ₹1,812 crore, a 5% increase year-on-year, with EBITDA growing by 10% to ₹523 crore and net profits rising by 19% to ₹279 crore. The company also highlighted its strategic investments in new modalities like Gene Therapy and Antibody-Drug Conjugates (ADCs), with significant capex planned for ongoing growth projects, including a new 532-acre site in Vizag. The company also declared an interim dividend of ₹1.20 per share.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.